Polio outbreaks in Cameroon following the COVID-19 pandemic.
COVID-19
Cameroon
Polio
circulating vaccine-derived poliovirus
outbreak
vaccine
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
05
2022
accepted:
09
06
2023
medline:
5
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Polio is an infectious and disabling life-threatening disease caused by the poliovirus. This disease is prevented through vaccination. Though this viral infection has been eliminated in most parts of the world, a few countries are still endemic to wild poliovirus. In 2020, the World Health Organization (WHO) African Region, including Cameroon, was certified free of wild poliovirus. Some countries recurrently report circulating vaccine-derived poliovirus cases (cVDPV) despite recorded achievements. Also, the risk of importing poliovirus from endemic settings remains, particularly in the context of coronavirus disease (COVID-19). This study aimed to assess the state of polio in Cameroon and identify the situation during COVID-19. A data review was conducted from February to March 2023. Data on polio cases and vaccination coverage per region of Cameroon were reviewed from 2014 to 2022. Data were analyzed with Microsoft Excel, and the results were presented as proportions. The last wild poliovirus was reported in Cameroon in 2014, and the country benefitted from a response. No case of poliovirus was detected in the country from 2015 to 2018. After that, an increasing number of type two cVDPV were reported across 50% of the country's regions from 2019 to 2022. The outbreaks benefitted from responses with various oral polio vaccines, including the type two novel oral polio vaccine (nOPV-2). Though wild polioviruses have been eliminated in most countries, including Cameroon, cVDPV remains a significant problem. There is an urgent need to strengthen disease surveillance and vaccination to prevent cVDPV-2 in this country, particularly in the COVID-19 context.
Identifiants
pubmed: 37663631
doi: 10.11604/pamj.2023.45.90.35332
pii: PAMJ-45-90
pmc: PMC10474802
doi:
Substances chimiques
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright: Andreas Ateke Njoh et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Arch Pediatr. 2021 Aug;28(6):441-450
pubmed: 34140219
BMJ. 2005 Jun 4;330(7503):1314-8
pubmed: 15933355
Pan Afr Med J. 2022 Mar 14;41:201
pubmed: 35685114
Int J Infect Dis. 2022 Jun;119:201-209
pubmed: 35398300
Confl Health. 2021 Feb 10;15(1):8
pubmed: 33568157
Lancet Infect Dis. 2017 Oct;17(10):1069-1079
pubmed: 28693854